Fierce Biotech
- A2A Pharma
- May 16, 2019
- 1 min read
Updated: Feb 7, 2020
top of page
Search
Recent Posts
See AllMay 27, 2025 - A2A Pharmaceuticals a clinical stage oncology company with the lead asset AO-252, a PPI inhibitor of TACC3 which is a 1st...
Biomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations...
bottom of page
Comments